A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies

Supportive Care in Cancer

Volumn 23, Issue 8, 2015, Pages 2231-2244

  Chan, Alexandre ^a   Cameron, Michael C ^b   Garden, Benjamin ^c   Boers Doets, Christine B ^d,e   Schindler, Katja ^c,f   Epstein, Joel B ^g   Choi, Jennifer ^h   Beamer, Laura ⁱ   Roeland, Eric ^j   Russi, Elvio G ^k   Bensadoun, René Jean ^l   Teo, Yi Ling ^a   Chan, Raymond J ^m   Shih, Vivianne ⁿ   Bryce, Jane ^o   Raber Durlacher, Judith ^p   Gerber, Peter Arne ^q   Freytes, César O ^r   Rapoport, Bernardo ^s   LeBoeuf, Nicole ^t   Sibaud, Vincent ^u   Lacouture, Mario E ^c   more..

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d IMPAQTT Research and Consultancy   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Universitatsklinik fur Dermatologie   (Austria)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NORTHERN ILLINOIS UNIVERSITY   (United States)

^j UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^k S Croce e Carle City Hospital   (Italy)

^l Department of Radiotherapy   (France)

^m QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

ⁿ DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^o NATIONAL CANCER INSTITUTE   (Italy)

^p ACADEMIC MEDICAL CENTER   (Netherlands)

^q HEINRICH HEINE UNIVERSITY   (Germany)

^r UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^s Medical Oncology Centre of Rosebank   (South Africa)

^t DANA FARBER CANCER INSTITUTE   (United States)

^u University Institute of Cancer Oncopole   (France)

more..

Author keywords

Dermatologic adverse events; Health related quality of life; Patient reported outcomes; Targeted cancer therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; DERMATOLOGIC ADVERSE EVENTS; DERMATOLOGY LIFE QUALITY INDEX; DIELH 24; DRUG INDUCED DISEASE; FUNCTIONAL ASSESSMENT; HAND FOOT SYNDROME; HUMAN; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOME; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN DISEASE; SKIN DISEASE ASSESSMENT; SKIN TOXICITY; SKINDEX 16; SKINDEX 29; SYSTEMATIC REVIEW; ADVERSE EFFECTS; CHEMICALLY INDUCED; NEOPLASMS; PSYCHOLOGY; QUESTIONNAIRE; SKIN DISEASES;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRES; SKIN DISEASES;

EID: 84933183142     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2564-x     Document Type: Article

References (30)

1. Agha R, Kinahan K, Bennett CL, Lacouture ME (2007) Dermatologic challenges in cancer patients and survivors. Oncology (Williston Park, NY) 21(12):1462–1472, discussion 1473, 1476, 1481 passim
2. Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, Rosenbaum SE, Lacouture ME (2010) Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116(16):3916–3923. doi:10.1002/cncr.25090
3. Chen A, Acharya A, Setser A (2013) Grading dermatologic adverse events in clinical trials using CTCAE v4.0. In: dermatologic principles and practice in oncology. Wiley, New Jersey, pp 47–59. doi:10.1002/9781118590638.ch5
4. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D (2006) Patient versus clinician symptom reporting using the national cancer institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol 7(11):903–909. doi:10.1016/s1470-2045(06)70910-x
5. Basch E (2012) Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health: J Int Soc Pharmacoeconomics Outcomes Res 15(3):401–403. doi:10.1016/j.jval.2012.03.1385
6. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol: Off J Am Soc Clin Oncol 28(8):1351–1357. doi:10.1200/jco.2008.21.7828
7. Cano SJ, Klassen A, Pusic AL (2009) The science behind quality-of-life measurement: a primer for plastic surgeons. Plast Reconstr Surg 123(3):98e–106e. doi:10.1097/PRS.0b013e31819565c1
8. Aaronson N, Alonso J, Burnam A, Lohr KN, Patrick DL, Perrin E, Stein RE (2002) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res Int J Qual Life Asp Treat Care Rehab 11(3):193–205
9. Nardone B, Hensley JR, Kulik L, West DP, Mulcahy M, Rademaker A, Lacouture ME (2012) The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol: JDD 11(11):e61–65
10. Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, Lacouture ME (2013) Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 14(4):327–333. doi:10.1007/s40257-013-0021-0
11. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the north central cancer treatment group (N03CB). Cancer 113(4):847–853. doi:10.1002/cncr.23621
12. Andreis F, Rizzi A, Mosconi P, Braun C, Rota L, Meriggi F, Mazzocchi M, Zaniboni A (2010) Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study. Health Qual Life Outcomes 8:40. doi:10.1186/1477-7525-8-40
13. Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, Besse B, Robert C (2009) Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 161(3):515–521. doi:10.1111/j.1365-2133.2009.09214.x
14. Unger K, Niehammer U, Hahn A, Goerdt S, Schumann M, Thum S, Schepp W (2013) Treatment of metastatic colorectal cancer with cetuximab: influence on the quality of life. Z Gastroenterol 51(8):733–739. doi:10.1055/s-0033-1335064
15. Wagner LI, Berg SR, Gandhi M, Hlubocky FJ, Webster K, Aneja M, Cella D, Lacouture ME (2013) The development of a functional assessment of cancer therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Support Care Cancer: Off J Multinatl Assoc Support Care in Cancer 21(4):1033–1041. doi:10.1007/s00520-012-1623-4
16. Boers-Doets CB, Gelderblom H, Lacouture ME, Epstein JB, Nortier JW, Kaptein AA (2013) Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events. Support Care Cancer: Off J Multinatl Assoc Support Care Cancer 21(7):1919–1926. doi:10.1007/s00520-013-1752-4
17. Sibaud V, Dalenc F, Chevreau C, Roche H, Delord JP, Mourey L, Lacaze JL, Rahhali N, Taieb C (2011) HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 16(10):1469–1478. doi:10.1634/theoncologist. 2011-0033
18. Taieb C, Sibaud V (2009) PCN82 HFS 14: a specific quality of life instrument for patients with hand-foot syndrome. Value Health 12(3):A52
19. Teo YL, Chong XJ, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A (2014) Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation. Cancer Chemother Pharmacol 73(2):381–388. doi:10.1007/s00280-013-2360-1
20. Chren MM (2012) The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin 30(2):231–236. doi:10.1016/j.det.2011.11.003, xiii
21. Chren MM, Lasek RJ, Sahay AP, Sands LP (2001) Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 5(2):105–110. doi:10.1007/s102270000010
22. Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210–216
23. Lewis V, Finlay AY (2004) 10 years experience of the Dermatology Life Quality Index (DLQI). The journal of investigative dermatology Symposium proceedings / the Society for Investigative Dermatology, Inc [and] European Society for Dermatological Research 9 (2):169–180. doi:10.1111/j.1087-0024.2004.09113.x
24. Finlay AY, Basra MK, Piguet V, Salek MS (2012) Dermatology life quality index (DLQI): a paradigm shift to patient-centered outcomes. J Invest Dermatol 132(10):2464–2465. doi:10.1038/jid.2012.147
25. Schafer T, Staudt A, Ring J (2001) German instrument for the assessment of quality of life in skin diseases (DIELH). Internal consistency, reliability, convergent and discriminant validity and responsiveness. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 52(7):624–628
26. Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, Lacouture ME (2012) Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0. J Am Acad Dermatol 67(5):1025–1039. doi:10.1016/j.jaad.2012.02.010
27. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72(3–4):152–159. doi:10.1159/000112795
28. Wagner LI, Lacouture ME (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park, NY) 21(11):34–36
29. Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, Selby PJ (2004) Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol Off J Am Soc Clin Oncol 22(4):714–724. doi:10.1200/jco.2004.06.078
30. Wagner LI, Cella D (2013) Psychosocial issues in oncology: clinical management of psychosocial distress, health-related quality of life, and special considerations in dermatologic oncology. In: dermatologic principles and practice in oncology. Wiley, Hoboken, pp 60–68. doi:10.1002/9781118590638.ch6